Related Experiment Videos
In vivo 31P MRS of experimental tumours
J D de Certaines1, V A Larsen, F Podo
1Laboratoire de Résonance Magnétique en Biologie et Médecine, Université de Rennes I, France.
Abstract:
More than 50% of cancers fail to respond to any individual treatment and tumour follow-up after treatment plays a major role in routine therapy planning and pharmacological research. Today, MRS is the only technological approach providing non-invasive access to tumour biochemistry. Ten years ago, expectations were raised concerning 31P MRS as an exciting and promising technical approach to the study of tumours. However the expectations have not always come to fruition. How close are we now to seeing routine 31P NMR in clinical oncology? This review of the 127 published papers shows spectroscopy results in more than 150 experimental animal tumour models. These tumour/host/treatment systems provide us with a useful basis to evaluate the current state of the art, summarize the basic knowledge presently available, determine the key points underlying the present disappointment of some clinical oncologists and stimulate new basic research. The information collected concerns the discussion of the reliability of experimental models in oncology, the technical improvement of magnetic resonance technology and the monitoring of bioenergetic status, pH regulation and phospholipid metabolism in treated and untreated tumours. Recent advances (two-thirds of the papers have been published in the last 5 years) seem to provide more optimistic perspectives than those generally accepted a few years ago, in the depressing period following early pioneering work.
Insights
Phosphorus-31 magnetic resonance spectroscopy (31P MRS) offers non-invasive tumor biochemistry insights. Recent advances suggest 31P MRS may soon become a valuable tool in clinical oncology for treatment monitoring.
Area of Science:
- Oncology
- Biochemistry
- Medical Imaging
Background:
- Over 50% of cancers resist individual treatments, necessitating effective tumor follow-up.
- Magnetic Resonance Spectroscopy (MRS) is the sole non-invasive method for assessing tumor biochemistry.
- Early expectations for 31P MRS in oncology have not been fully realized.
Purpose of the Study:
- To evaluate the current status and future potential of 31P MRS in clinical oncology.
- To analyze the reliability of experimental animal tumor models for MRS studies.
- To identify factors contributing to the underutilization of 31P MRS in clinical settings.
Main Methods:
- Systematic review of 127 published papers on 31P MRS in over 150 experimental animal tumor models.
- Analysis of technical advancements in magnetic resonance technology.
- Evaluation of bioenergetic status, pH regulation, and phospholipid metabolism monitoring.
Main Results:
- Recent advancements, particularly in the last five years, show promising developments in 31P MRS technology and application.
- Data from experimental models provide a basis for understanding tumor biochemistry and response to treatment.
- Key areas of investigation include bioenergetics, pH regulation, and phospholipid metabolism.
Conclusions:
- Despite past disappointments, recent progress in 31P MRS suggests a more optimistic outlook for its routine use in clinical oncology.
- Further research is needed to overcome current limitations and fully integrate 31P MRS into cancer diagnostics and therapy.
- 31P MRS holds potential for improved tumor monitoring and personalized treatment strategies.